A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Inclusion Criteria: * Subject has histologic or cytologic confirmation of advanced solid tumors that is refractory to standard therapy or for which no standard therapy is available * Subject has measurable or nonmeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 * Subject has resolution to grade ≤1 by NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Version 4.03 of all clinically significant toxic effects of prior treatment * Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Subject has adequate hematologic, hepatic, renal, and coagulation function * Subject has a life expectancy greater than 3 months * Subject agrees to use adequate contraception during the study period and for 12 weeks after last dose of study therapy * Subject must undergo mandatory biopsies, including one pretreatment and one post treatment tumor biopsy procedure Exclusion Criteria: * Subject has experienced acute pathologic fracture or spinal cord compression within 28 days prior to first dose of study therapy * Subject has a known hypersensitivity to monoclonal antibodies or to agents of similar biologic composition as IMC-CS4. * Subject has received treatment with any monoclonal antibodies within 4 weeks prior to first dose of study therapy * Subject has undergone a major surgical procedure, open biopsy, radiofrequency ablation or has experienced a significant injury within 28 days prior to enrollment * Subject has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer or in situ neoplasm * Subject has an ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, active bleeding or any other serious uncontrolled medical disorder * Subject has known or suspected primary brain or leptomeningeal metastases * Subject has leukemia or lymphoma * Subject is know to have active tuberculosis, leishmaniasis, or listeriosis * Subjects with known history, or clinical or laboratory evidence of liver disease * Subject has a known active hepatitis B or C infection, Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) * Subject if female, is pregnant or breastfeeding * Subject has received an organ transplant